aTyr Pharma
ATYR
50 hedge funds and large institutions have $143M invested in aTyr Pharma in 2015 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 19 increasing their positions, 13 reducing their positions, and 6 closing their positions.
46% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 13
0% more funds holding
Funds holding: 50 → 50 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
1.33% less ownership
Funds ownership: 62.67% → 61.34% (-1.3%)
30% less capital inflows, than outflows
Capital inflows: $7.48M | Capital outflows: $10.7M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock Fund Advisors
San Francisco,
California
|
+$2.86M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.27M |
| 3 |
RS Investment Management
San Francisco,
California
|
+$1.26M |
| 4 |
Rock Springs Capital Management
Baltimore,
Maryland
|
+$266K |
| 5 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$260K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deerfield Management
New York
|
-$4.74M |
| 2 |
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.75M |
| 3 |
Magnetar Financial
Evanston,
Illinois
|
-$1.71M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$694K |
| 5 |
Putnam Investments
Boston,
Massachusetts
|
-$528K |
ATYR Hedge Fund Activity: Q4 2015 in Review
50 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q4 2015, worth a combined $143M — down 6% from $152M a quarter earlier.
Fund positioning in ATYR was balanced in Q4 2015: 6 funds opened new positions, 6 closed out, 19 added to existing stakes and 13 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $2.86M. The largest seller was Deerfield Management, exiting entirely with an estimated $4.74M sold.
- 50 institutional investors held aTyr Pharma (ATYR) as of Q4 2015, unchanged from Q3 2015.
- Funds reported $143M of aTyr Pharma stock for Q4 2015, down 6% quarter-over-quarter.
- 6 funds opened new aTyr Pharma positions in Q4 2015 and 6 closed out, a net change of 0 holders.
- The largest aTyr Pharma buyer in Q4 2015 was BlackRock Fund Advisors, an estimated $2.86M added.
- The largest aTyr Pharma seller in Q4 2015 was Deerfield Management, an estimated $4.74M sold.
Based on aggregated 13F filings for Q4 2015.